Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363863 | 0.94 | SMN1; SMN2 (0.58) | SMN1; SMN2RECQLKDM4EALDH1A1LMNA | |
| SCHEMBL15225951 | 0.92 | SMN1; SMN2 (0.71) | SMN1; SMN2RECQLKDM4EALDH1A1LMNA | |
| SCHEMBL20271516 | 0.90 | SMN1; SMN2 (0.73) | SMN1; SMN2RECQLKDM4EALDH1A1LMNA | |
| SCHEMBL5723140 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2RECQLKDM4EALDH1A1LMNA | |
| Bicarbonate SCHEMBL15226074 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2RECQLKDM4EALDH1A1LMNA | |
| SCHEMBL28045965 | 0.84 | KDM4E (0.61) | SMN1; SMN2RECQLKDM4EALDH1A1HTT | |
| SCHEMBL13478276 | 0.82 | LMNA (0.59) | SMN1; SMN2ALDH1A1LMNAGAAHTT | |
| SCHEMBL11253764 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2RECQLKDM4EALDH1A1LMNA | |
| SCHEMBL30221947 | 0.80 | MEN1 (0.59) | SMN1; SMN2RECQLKDM4EALDH1A1LMNA | |
| SCHEMBL23093557 | 0.77 | CA1 (0.54) | SMN1; SMN2RECQLKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1651595-A2 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20050009871-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | claimed |
| US-11554106-B2 | Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin | CHILDS, MARC (FR) | 2023-01-17 | — | — | US | disclosed |
| US-11484529-B2 | Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | OP2 Drugs (FR) | 2022-11-01 | — | — | US | disclosed |
| US-11400073-B2 | Prevention and treatment of benign prostatic hyperplasia using a selective inhibitor of the production of reactive oxygen species of mitochondrial origin | Petitjean, Olivier (FR) | 2022-08-02 | — | — | US | disclosed |
| US-11318113-B2 | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | OP2 Drugs (FR) | 2022-05-03 | — | — | US | disclosed |
| CN-108348781-B | Compounds for the treatment of diseases associated with the production of mitochondrial Reactive Oxygen Species (ROS) | OP2药品公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20210154175-A1 | DESMETHYLANETHOLE TRITHIONE DERIVATIVES FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | OP2 Drugs (FR) | 2021-05-27 | — | — | US | disclosed |
| US-20210052549-A1 | PREVENTION OF THE RISKS ASSOCIATED WITH DRUG-INDUCED QT INTERVAL PROLONGATION BY USING A SPECIFIC INHIBITOR OF THE PRODUCTION OF ROS OF MIOCHONDRIAL ORIGIN | CHILDS MARC (FR) | 2021-02-25 | — | — | US | disclosed |
| US-20200289461-A1 | PREVENTION AND TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN | PETITJEAN OLIVIER (FR) | 2020-09-17 | — | — | US | disclosed |
| US-20180256540-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | UNIVERSITÉ DE BORDEAUX (FR) | 2018-09-13 | — | — | US | disclosed |
| WO-2018162581-A1 | DESMETHYLANETHOLE TRITHIONE DERIVATIVES FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | OP2 Drugs (FR) | 2018-09-13 | — | — | WO | disclosed |
| EP-3347100-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | OP2 DRUGS (FR) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017042267-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | ORPHAN PARTNERS 2 (FR) | 2017-03-16 | — | — | WO | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-4337274-A | Flukicidal compounds | BURROUGHS WELLCOME CO. (US) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154175-A1 | DESMETHYLANETHOLE TRITHIONE DERIVATIVES FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | TXN2, ROS1, ERAL1 | SMN1; SMN2 710/4885RECQL 807/4885KDM4E 4330/4885 |
| US-20180256540-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | FH, TXNRD2, TXN2 | SMN1; SMN2 245/4885RECQL 761/4885KDM4E 4549/4885 |
| US-20210052549-A1 | PREVENTION OF THE RISKS ASSOCIATED WITH DRUG-INDUCED QT INTERVAL PROLONGATION BY USING A SPECIFIC INHIBITOR OF THE PRODUCTION OF ROS OF MIOCHONDRIAL ORIGIN | TXN2, ABAT, ACAT1 | SMN1; SMN2 2878/4885RECQL 598/4885KDM4E 2809/4885 |
| US-20200289461-A1 | PREVENTION AND TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN | MDH2, TXNRD2, SQOR | SMN1; SMN2 4698/4885RECQL 934/4885KDM4E 4304/4885 |
| US-20050009871-A1 | Ubiquitin ligase inhibitors | NEDD4, STUB1, UBE3A | SMN1; SMN2 3336/4885RECQL 1757/4885KDM4E 463/4885 |
| US-11400073-B2 | Prevention and treatment of benign prostatic hyperplasia using a selective inhibitor of the production of reactive oxygen species of mitochondrial origin | MDH2, TXNRD2, SQOR | SMN1; SMN2 4698/4885RECQL 934/4885KDM4E 4304/4885 |
| US-11318113-B2 | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | FH, TXNRD2, TXN2 | SMN1; SMN2 245/4885RECQL 761/4885KDM4E 4549/4885 |
| US-11554106-B2 | Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin | TXN2, ABAT, ACAT1 | SMN1; SMN2 2878/4885RECQL 598/4885KDM4E 2809/4885 |
| US-11484529-B2 | Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | TXN2, ROS1, ERAL1 | SMN1; SMN2 710/4885RECQL 807/4885KDM4E 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.